Aidoudi S, Guigon M, Lebeurier I, Caen J P, Han Z C
Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France.
Br J Haematol. 1996 Sep;94(3):443-8. doi: 10.1046/j.1365-2141.1996.d01-1821.x.
In vivo effects of platelet factor 4 (PF4) and tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) on haemopoietic progenitors were studied in mice treated with 5-fluorouracil (5-FU). The mice were injected with PF4 (40 micrograms/kg) or AcSDKP (4 micrograms/kg) twice at 6 h intervals, and 20 h after the second injection they were given one injection of 5-FU (150 mg/kg). 6, 8 and 13 d later the high proliferative potential-colony forming cell (HPP-CFC), burst-forming unit erythroid (BFU-E), colony forming unit granulocyte-macrophage (CFU-GM) colony forming unit megakaryocyte (CFU-MK), and megakaryocytes (MK) were examined. The results showed that the administration of PF4 or AcSKDP resulted in a significant increase in the number of HPP-CFC on days 6-8 and BFU-E and CFU-GM on day 8 when compared to 5-FU alone. Furthermore, PF4 was found to increase significantly the number of CFU-MK and MK on day 8, which was not observed with AcSDKP. However, both molecules had no obvious effect on peripheral blood cells. These data indicate that PF4 or AcSDKP accelerate the recovery in vivo of HPP-CFC, CFU-GM and BFU-E after 5-FU treatment but their effect may be different on megakaryocytic progenitors and suggests that both molecules may have a haemoprotective effect against chemotherapeutic agents.
在接受5-氟尿嘧啶（5-FU）治疗的小鼠中，研究了血小板因子4（PF4）和四肽N-乙酰丝氨酸-天冬氨酸-赖氨酸-脯氨酸（AcSDKP）对造血祖细胞的体内作用。小鼠每隔6小时注射一次PF4（40微克/千克）或AcSDKP（4微克/千克），共注射两次，在第二次注射后20小时，给它们注射一次5-FU（150毫克/千克）。在6、8和13天后，检测高增殖潜能集落形成细胞（HPP-CFC）、红系爆式集落形成单位（BFU-E）、粒-巨噬细胞集落形成单位（CFU-GM）、巨核细胞集落形成单位（CFU-MK）和巨核细胞（MK）。结果表明，与单独使用5-FU相比，在第6至8天给予PF4或AcSKDP可使HPP-CFC数量显著增加，在第8天可使BFU-E和CFU-GM数量显著增加。此外，发现PF4在第8天可使CFU-MK和MK数量显著增加，而AcSDKP未观察到这种情况。然而，这两种分子对外周血细胞均无明显影响。这些数据表明，PF4或AcSDKP可加速5-FU治疗后HPP-CFC、CFU-GM和BFU-E的体内恢复，但它们对巨核细胞祖细胞的作用可能不同，提示这两种分子可能对化疗药物具有血液保护作用。
